INSIGHTS INTO THE RAPIDLY GROWING OBESITY DRUG MARKET & A FOCUS ON THE SURGE IN IRISH CUSTOMERS USING REVOLUT TO TRADE SECURITIES

We look at how Novo Nordisk and Eli Lilly are set to face a new challenger in weight-loss race. As highlighted in our most recent podcast, the weight-loss drug market is a rapidly growing sector and one where new entrant to the market , Danish biotech group Zealand Pharma, is developing an alternative obesity treatment to compete with the big rivals. Plus, we examine the recent surge in Irish customers using Revolut to trade securities.

The rapidly growing obesity drug market, dominated by key players Novo Nordisk and Eli Lilly, has a new entrant, ready to compete with these two market leaders. Goldman Sachs sees the potential for the weight-loss drug market to grow to $100 billion by the end of the decade. This is further evidenced by other major pharmaceutical companies entering the market in recent times and by a desire for greater choice, given the ever-widening range of diseases associated with obesity. Zealand Pharma is one company for investors to watch out for. With alternative weight-loss treatments in development, Zealand could be a ripe target for acquisition, particularly if its alternative treatments achieve similar weight-loss, but with reduced side effects, sometimes associated with the current drugs available from the market leaders.

With a 22% surge in Revolut users buying securities in Ireland during 2023 ,we examine the most popular shares traded here and describes how Revolut users are reflecting the strong growth in stock markets generally last year. Revolut plans to roll out a bond-trading feature in 2024, all of which supports the recent growth in its company revenues posted for y/e 2022.

Revolut_Novo-Nordisk-25-01-24

Tel:  +353 1 70 70 000           or       info@seasprayfs.ie

Warning: The value of your investment may go down as well as up and you may lose some or all of the money you invest. Past performance is not a reliable guide to future performance. Investments denominated in a currency other than your base currency may be affected by changes in currency exchange rates.

https://seasprayfinancialservices.ie/important-disclosures/

Seaspray Financial Services Limited is regulated by the Central Bank of Ireland .

Registered in Ireland number 582920.  

Subscribe to our Updates